Abstract 5537
Background
The clinical potential of many promising anti-tumor drugs is restricted by their intrinsic physicochemical properties and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. To overcome these hurdles, we have developed a new drug delivery system based on polyurea/polyurethane nanocapsules (NCs), which might protect the loaded drug from premature degradation and specifically release it inside cancer cells. Polyurea/polyurethane polymers present amphoteric properties, thus, these NCs are anionic at basic pH and cationic at acid pH. Tumor microenvironment is slightly acidic (6.8-7) in comparison to healthy tissue (7.2-7.4); hence, NCs became cationic in the tumor area, what facilitates their internalization into tumor cells.
Methods
In order to study this novel delivery system, an analog of tambjamine has been loaded in these amphoteric NCs and their selectivity and antitumor properties have been analyzed in vitro comparing two pHs, one acidic (6.8) and another basic (7.5) by proliferation assays, flow cytometry and microscopy. Additionally, the toxicity and efficacy of this delivery approach has been evaluated in an orthotopic lung cancer mouse model.
Results
In vitro results showed higher levels of NCs uptake in tumor cells at pH 6.8, resulting in greater cytotoxic effects compared to those at pH 7.5. Toxicity studies in vivo showed a good tolerability to repeated administrations and furthermore, the encapsulation of the drug reduces its toxicity compared to the free compound, allowing its intravenously administration. Preliminary data show a tendency limiting tumor growth, suggesting that NCs have reached the tumor site and the drug has been released.
Conclusions
Altogether, we have developed a promising new drug delivery system based on polyurea/polyurethane nanocapsules loaded with a tambjamine analog in order to be specifically delivered in cancer cells through reductive conditions, facilitating drug transport to tumor, administration and improving drug safety.
Editorial acknowledgement
Legal entity responsible for the study
Universitat de Barcelona.
Funding
This work was partially supported by a grant from the Spanish government and the EU (PI18/00441).
Disclosure
C. Cuscó: Full / Part-time employment, Not currently employed at Ecopoltech. J. Bonelli: Full / Part-time employment: Ecopoltech. J. Rocas: Leadership role, Officer / Board of Directors: Ecopoltech. All other authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract